I like to keep things simple—I look for stocks that have strong price momentum, top Zacks Ranks, reasonable valuations and high growth forecasts. Momentum indicates that the market recognizes a winn
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Top-ranked stocks Urban Outfitters (URBN), Tenet Healthcare (THC), Five9 (FIVN), Marqeta (MQ) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here are the four discounted PEG-based value stocks that qualify our screening criteria- URBN, XRAY, LTM and EXEL.

2 Top Stocks to Buy With Less Than $100

08:00am, Friday, 30'th May 2025
When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE